Achondroplasia: Clinical Trials

8 trials for Achondroplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 2 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting. 8 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 38Completed 3, Active not recruiting 2, Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1
Phase 23Completed 1, Enrolling by invitation 1, Recruiting 1

Follow Achondroplasia: new trials by email Literature Review of Achondroplasia trials Research Report on Achondroplasia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial Evaluating the Efficacy and Safety of Navepegritide and Lonapegsomatropin in Achondroplasia
Dual therapy with navepegritide and lonapegsomatropin, Dual therapy with navepegritide and placebo for lonapegsomatropin, Dual therapy with lonapegsomatropin and placebo for navepegritide - Achondroplasia
Phase 3Not yet recruitingAscendis Pharma A/S1442026-11-012026-11-12
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
BMN 333, Vosoritide Injection [Voxzogo] - Achondroplasia
Phase 2 / Phase 3RecruitingBioMarin Pharmaceutical1602026-04-202026-10-22
Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia(AOBA Study)
KK8398 - Achondroplasia
Phase 3Active not recruitingKyowa Kirin Co., Ltd.132024-12-012026-10-08
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia
Infigratinib 0.25 mg/kg/day, Placebo Comparator 0.25 mg/kg/day - Achondroplasia
Phase 3CompletedQED Therapeutics, a BridgeBio company1142023-11-102026-03-17
A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia
TransCon CNP - Achondroplasia
Phase 2 / Phase 3Enrolling by invitationAscendis Pharma Growth Disorders A/S1402023-06-212026-08-17
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Children With Achondroplasia
Navepegritide (TransCon CNP), Placebo for Navepegritide (TransCon CNP) - Achondroplasia
Phase 2 / Phase 3CompletedAscendis Pharma Growth Disorders A/S842023-03-032026-07-14
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
BMN 111 - Achondroplasia
Phase 3Active not recruitingBioMarin Pharmaceutical1192017-12-122026-03-13
A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
BMN 111, Placebo - Achondroplasia
Phase 3CompletedBioMarin Pharmaceutical1212016-12-122022-03-02

Narrower conditions

Bone Diseases (4)  ·  Dwarfism (4)  ·  Genetic Diseases, Inborn (4)  ·  Musculoskeletal Diseases (4)  ·  Osteochondrodysplasias (4)  ·  Bone Diseases, Developmental (2)  ·  Mucopolysaccharidosis IV (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8)  ·  Bone Diseases, Developmental (6)  ·  Bone Diseases (4)  ·  Dwarfism (4)  ·  Endocrine System Diseases (4)  ·  Genetic Diseases, Inborn (4)  ·  Musculoskeletal Diseases (4)  ·  Osteochondrodysplasias (4)  ·  Carbohydrate Metabolism, Inborn Errors (1)  ·  Connective Tissue Diseases (1)  ·  Lysosomal Storage Diseases (1)  ·  Metabolic Diseases (1)  ·  Metabolism, Inborn Errors (1)  ·  Mucinoses (1)  ·  Mucopolysaccharidoses (1)

Interventions

vosoritide (3)  ·  infigratinib (1)  ·  lonapegsomatropin (1)

Sponsors

BioMarin Pharmaceutical (3)  ·  Ascendis Pharma Growth Disorders A/S (2)  ·  Ascendis Pharma A/S (1)  ·  Kyowa Kirin Co., Ltd. (1)  ·  QED Therapeutics, a BridgeBio company (1)

Countries

Australia (6)  ·  United States (6)  ·  Spain (5)  ·  United Kingdom (5)  ·  Canada (4)  ·  Japan (4)  ·  Germany (3)  ·  Denmark (2)  ·  France (2)  ·  Ireland (2)  ·  Italy (2)  ·  New Zealand (2)  ·  Turkey (Türkiye) (2)  ·  Argentina (1)  ·  Austria (1)

Top investigators

Yu Sato (1)

Results publications

PMID 38649657, PMID 39305160, PMID 39740666, PMID 34431071, PMID 41247754, PMID 42144862, PMID 42370681

NIH funding

2015 (1), 2017 (1)